In this review
The $133 and $166 headlines are not the bills
The semaglutide product requires $399 today; tirzepatide requires $499. Each then renews for the same amount every eleven weeks. Homepage $133 and $166 monthly presentations should stay attached to those actual charges. The plan is described as three months, but the recurring payment interval is shorter than three calendar months. [1] [2] [3]
Checkout terms require stopping renewals through the account at least two business days before billing. Non-approved renewals receive the full renewal charge back without the $50 fee. That is more useful budget information than a broad cancel-anytime badge, which does not refund an existing order. [4]
Compare upfront and repeating payments in the full GLP-1 cost planner.
Transfer protection is a documented application
The checkout policy applies only to transfers of compounded semaglutide or tirzepatide prescriptions. Evidence of the current prescription and recent use must reach the platform before provider review. A lower approved strength or non-approval may qualify for a first-order refund under its conditions. [4]
The clinician retains the prescription decision. The policy has a twelve-hour telephone claim window, and it excludes a buyer who is approved at the documented strength but simply decides not to proceed. A specific pharmacy-return arrangement can apply to a qualifying shipped transfer claim; it is not a general prescription-return policy. Do not treat the policy as a promised treatment level. [4]
For another term-based purchase, read our Bodybuilding Health+ bundle review.
First-order cancellation needs clarification
Payment comes before intake and the product pages promise a full refund after non-approval. For an approved first order, checkout terms require a call within twelve hours of completed review and deduct $50. The separate refund page instead describes a discretionary $50-deducted refund requested by email within twenty-four hours. [1] [2] [4] [5]
Those contact methods and deadlines disagree. General terms also label professional fees nonrefundable. Establish the applicable written conditions before paying rather than assuming the longer window applies. Outside the specific transfer exception, dispensed medicine is nonrefundable. [4] [5] [6]
Compare a different published approval remedy in our Oak approval-and-refund review.
For a different clinical access and pharmacy-cancellation arrangement, read our YOURx Health care-and-cancellation review.
Medication access is not a branded-product comparison
The plan includes medication through a partner pharmacy if approved. Using a different pharmacy can mean paying it separately. Provider messaging and a private community are described, but they do not establish scheduled nutrition visits, a complete laboratory panel or universal product availability. Confirm the preparation and ongoing clinical contact. [3] [4] [6]
Compounded drugs are not FDA-approved generic equivalents. FDA policy imposes patient-specific conditions after GLP-1 shortage resolution. The service comparison should therefore address the actual prescription and care need, rather than borrow branded-trial outcomes or choose a bundle because it adds NAD+ or sermorelin. [7] [8]
Keep function and lean mass beside scale change with the GLP-1 body-composition evidence.
Understanding the cost
Semaglutide $399 and tirzepatide $499 upfront for advertised three-month plans, renewing at the same amount every eleven weeks. Medication through a partner pharmacy is included if approved; another pharmacy charges separately. No monthly installment or universal strength guarantee.
Build your cost estimateSources
- HelloWellness: semaglutide initial bill and recurring plan
- HelloWellness: tirzepatide initial bill and recurring plan
- HelloWellness: current catalogue, provider messaging and payment-before-intake pathway
- HelloWellness: plan-specific subscription, cancellation and transfer terms
- HelloWellness: separate refund and delivered-package policy
- HelloWellness: independent clinical roles and pharmacy costs
- FDA: compounded drugs are not FDA-approved products
- FDA: current patient-specific GLP-1 compounding conditions
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.